000203298 001__ 203298
000203298 005__ 20210129220334.0
000203298 0247_ $$2doi$$a10.1186/s12974-015-0361-1
000203298 0247_ $$2Handle$$a2128/9046
000203298 0247_ $$2WOS$$aWOS:000359354300001
000203298 0247_ $$2altmetric$$aaltmetric:4409885
000203298 0247_ $$2pmid$$apmid:26268846
000203298 037__ $$aFZJ-2015-05272
000203298 041__ $$aEnglish
000203298 082__ $$a610
000203298 1001_ $$0P:(DE-Juel1)156467$$aRitter, Christian$$b0
000203298 245__ $$aChronic inflammatory demyelinating polyneuropathy (CIDP): change of serum IgG dimer levels during treatment with intravenous immunoglobulins
000203298 260__ $$aLondon$$bBioMed Central$$c2015
000203298 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1439902180_25191
000203298 3367_ $$2DataCite$$aOutput Types/Journal article
000203298 3367_ $$00$$2EndNote$$aJournal Article
000203298 3367_ $$2BibTeX$$aARTICLE
000203298 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000203298 3367_ $$2DRIVER$$aarticle
000203298 520__ $$aBackgroundIntravenous immunoglobulin (IVIg) is an effective treatment in chronic inflammatory demyelinating polyneuropathy (CIDP). In most patients, the optimal IVIg dose and regime is unknown. Polyvalent immunoglobulin (Ig) G form idiotypic/anti-idiotypic antibody pairs in serum and IVIg preparations. We determined IgG dimer levels before and after IVIg treatment in CIDP patients with the aim to explore their utility to serve as a surrogate marker for treatment response.MethodsIgG was purified from serum of five controls without treatment, as well as from serum of 16 CIDP patients, two patients with Miller Fisher syndrome (MFS), and one patient with myasthenia gravis before and after treatment with IVIg. IgG dimer levels were determined by size exclusion chromatography. IgG dimer formation was correlated with clinical response to IVIg treatment in CIDP. Re-monomerized IgG dimer fractions were analyzed for immunoreactivity against peripheral nerve tissue.ResultsIgG dimer levels were significantly higher in post- compared to pre-IVIg infusion samples. Low post-treatment IgG dimer levels in CIDP patients were associated with clinical worsening during IVIg treatment. Re-monomerized IgG dimer fractions from CIDP patients showed immunoreactivity against peripheral nerve tissue, whereas similarly treated samples from MFS patients showed immunoreactivity against GQ1b.ConclusionAssessment of IgG dimer levels could be a novel approach to monitor CIDP patients during IVIg treatment, but further studies in larger cohorts are warranted to explore their utility to serve as a potential therapeutic biomarker for IVIg treatment response in CIDP.
000203298 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000203298 588__ $$aDataset connected to CrossRef
000203298 7001_ $$0P:(DE-HGF)0$$aBobylev, Ilja$$b1
000203298 7001_ $$0P:(DE-HGF)0$$aLehmann, Helmar C.$$b2$$eCorresponding author
000203298 773__ $$0PERI:(DE-600)2156455-3$$a10.1186/s12974-015-0361-1$$gVol. 12, no. 1, p. 148$$n1$$p148$$tJournal of neuroinflammation$$v12$$x1742-2094$$y2015
000203298 8564_ $$uhttps://juser.fz-juelich.de/record/203298/files/s12974-015-0361-1.pdf$$yOpenAccess
000203298 8564_ $$uhttps://juser.fz-juelich.de/record/203298/files/s12974-015-0361-1.gif?subformat=icon$$xicon$$yOpenAccess
000203298 8564_ $$uhttps://juser.fz-juelich.de/record/203298/files/s12974-015-0361-1.jpg?subformat=icon-1440$$xicon-1440$$yOpenAccess
000203298 8564_ $$uhttps://juser.fz-juelich.de/record/203298/files/s12974-015-0361-1.jpg?subformat=icon-180$$xicon-180$$yOpenAccess
000203298 8564_ $$uhttps://juser.fz-juelich.de/record/203298/files/s12974-015-0361-1.jpg?subformat=icon-640$$xicon-640$$yOpenAccess
000203298 8564_ $$uhttps://juser.fz-juelich.de/record/203298/files/s12974-015-0361-1.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000203298 909CO $$ooai:juser.fz-juelich.de:203298$$pdnbdelivery$$pVDB$$pdriver$$popen_access$$popenaire
000203298 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)156467$$aForschungszentrum Jülich GmbH$$b0$$kFZJ
000203298 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000203298 9141_ $$y2015
000203298 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000203298 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000203298 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000203298 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEUROINFLAMM : 2013
000203298 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000203298 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000203298 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000203298 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000203298 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000203298 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000203298 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000203298 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000203298 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000203298 920__ $$lyes
000203298 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000203298 980__ $$ajournal
000203298 980__ $$aVDB
000203298 980__ $$aUNRESTRICTED
000203298 980__ $$aI:(DE-Juel1)INM-3-20090406
000203298 9801_ $$aFullTexts